There is an increasing interest in the potential use of cannabinoid onsite pharmaceuticals Troy, MT for many health conditions. However, despite the growing number of legal cannabis markets like cannabinoid pharmaceutical companies, only a small number of these drugs have been rigorously tested for safety and efficacy.
The most common of these is D9-tetrahydrocannabinol (D9-THC), which the FDA and EMA approved for chemotherapy-induced nausea and vomiting (CINV). Other compounds, such as nabilone [59, 60] and WIN55212-2, have been shown to reduce intraocular pressure in patients with glaucoma.
Chronic pain is a common condition that affects nearly 8 million Canadians. It can affect people’s daily lives, making it difficult to work and play.
The pain you feel comes from nerve cells that send messages from the body to your brain. Usually, the signals stop when you heal from an injury or a disease. But with chronic pain, the letters keep going even after you heal.
Unlike acute pain, chronic pain can last for months or even years. It can affect every part of your body.
There are many causes of chronic pain. Sometimes it can be caused by a long-lasting illness or an injury that hasn’t healed. Other times it may be caused by a change in how your body’s chemicals work.
Several studies have shown that cannabinoids inhibit tumor cell proliferation, induce apoptosis, and block angiogenesis. WIN 55,212-2, for example, was found to arrest prostate cancer cells in the G0/G1 phase via CB2 receptor-dependent signaling.
In addition, several studies have indicated that cannabinoids are also capable of suppressing tumor invasiveness and metastasis. This was achieved through the downregulation of chemokine receptors such as CCCH1 and CXCR4 and through the inhibition of extracellular matrix proteolysis.
There are currently no clinical data on the use of cannabinoid compounds in treating cancer. Still, research into this field is ongoing, and the results of such trials are expected to be positive. However, it should be noted that several potential adverse effects may arise from applying cannabinoid compounds. Some of these include:
Tourette’s Syndrome is a neurological disorder characterized by repeated uncontrollable movements or sounds (called tics). Tics may involve the direction of one or more muscle groups or the sound of a person’s voice.
Tics can vary in type, frequency, location, and severity. They can also come and go over time.
They can be simple or complex and can occur anywhere on the body. They can include jerking, blinking, twisting, tapping, and other sudden movements or sounds.
These tics can be mild or severe and interfere with communication, daily function, and quality of life. Treatment for tics includes a combination of medications and behavioral therapy.
A clinical trial has shown that a cannabinoid-based drug candidate called THX-TS01, developed by Israel-based Therapix Biosciences, improves symptoms in patients with Tourette’s Syndrome. The company is now working to develop the medication for commercial production.
Symptoms of MS can be challenging to manage, and many patients with MS wish they had a drug to help relieve symptoms. A survey of people with MS suggests a high demand for symptomatic treatments in this patient population (Banwell, 2016; Hazekamp 2013; Kindred 2017).
The underlying cause of MS is unknown, but it is thought to be an autoimmune disorder that affects the central nervous system (CNS). This is caused by an attack on the myelin that protects nerve fibers in the brain and spinal cord.
A diagnosis of MS is made by a doctor who has tested the patient’s memory, and vision or performed MRI scans to look for changes in the brain and spinal cord. Several types of MS can be diagnosed, but the most common is relapsing-remitting MS.
Relapses can worsen over days, weeks, or months. They may occur without warning or after a period of illness or stress. These attacks are followed by periods of reduced or no symptoms, known as remissions.